Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1997 Feb 22;349(9051):528-32.
doi: 10.1016/s0140-6736(97)80085-2.

Randomised controlled trial of hydroquinine in muscle cramps

Affiliations
Free article
Clinical Trial

Randomised controlled trial of hydroquinine in muscle cramps

P H Jansen et al. Lancet. .
Free article

Abstract

Background: Although quinine and hydroquinine are commonly prescribed for muscle cramps, controlled clinical trials of these drugs have reported mixed findings about efficacy. We investigated hydroquinine therapy in otherwise healthy adults who had frequent, ordinary muscle cramps.

Methods: This randomised, double-blind, placebo-controlled, parallel-group trial consisted of three consecutive 2-week periods: qualification, treatment, and washout, 68 women and 44 men who had at least three muscle cramps per week were enrolled. During the treatment period, participants were randomly assigned 300 mg daily dose of hydroquinine hydrobromide dihydrate (54 participants) or placebo (58). The frequency, severity (1-10), duration, and location of muscle cramps, as well as any side-effects, were recorded by participant in daily diaries. The primary outcome measures were the number of muscle cramps and the number of days during which the participants had muscle cramps (cramp-days).

Findings: We excluded five participants from both groups from the analysis. Thus, data from 49 hydroquinine-group participants and 53 placebo-group participants were analysed. In both groups the total number of muscle cramps and the number of cramp-days decreased during the treatment period compared with the qualification period. However, these improvements were greater in the hydroquinine group than in the placebo group. The hydroquinine-group participants reported a median of 8 (95% CI 7-12) fewer cramps and median of 3 (1-4) fewer cramp-days, whereas those on placebo reported only 3 (0-5) fewer cramps and 1 (0-5) fewer cramp-days. 32 (65%) of participants in the hydroquinine group had a 50% or greater reduction in the number of muscle cramps. After the onset of cramps, hydroquinine did not reduce the severity or duration of cramps. We also found a sustained effect after treatment had stopped. Hydroquinine was well tolerated, and resulted in only mild side-effects.

Interpretation: In our study, 300 mg hydroquinine was safe to take in the short-term and significantly more effective than placebo in the prevention of frequent, ordinary muscle cramps. This therapeutic effect outlasted the duration of treatment.

PubMed Disclaimer

Comment in

  • Laparoscopic surgery.
    Garden OJ. Garden OJ. Lancet. 1997 May 3;349(9061):1323. doi: 10.1016/s0140-6736(05)62535-4. Lancet. 1997. PMID: 9142083 No abstract available.
  • Laparoscopic surgery.
    O'Dwyer PJ. O'Dwyer PJ. Lancet. 1997 May 3;349(9061):1323-4. doi: 10.1016/s0140-6736(05)62536-6. Lancet. 1997. PMID: 9142084 No abstract available.
  • Laparoscopic surgery.
    Matz R. Matz R. Lancet. 1997 May 3;349(9061):1324. doi: 10.1016/S0140-6736(05)62537-8. Lancet. 1997. PMID: 9142085 No abstract available.

Publication types